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A number of anticoagulants are available in clinical use to preserve blood 
samples in liquid form until a suitable time for laboratory testing. 
Rotational thromboelastography is usually performed on a blood sample 
that has been anticoagulated with sodium citrate and then recalcified 
immediately prior to testing. 
In our institution we have had shortages of citrated Vacutainer® sample 
tubes. The use of a single in vitro anticoagulant promises to cut costs, 
simplify laboratory processes as well as limit the amount of blood drawn 
from patients.  
This together with the known problems with using citrate as an 
anticoagulant for viscoelastic testing (VET) prompted us to investigate the 




Blood samples from 20 healthy volunteers were divided into citrated and 
EDTA Vacutainer® tubes. A ROTEM EXTEM® assay was performed on 
each sample in both groups following the manufacturer’s guidelines. 
Clotting time (CT), clot formation time (CFT), alpha angle (α-angle) and 
maximum clot firmness (MCF) results were compared. Ionised calcium 
concentrations were measured on each sample before and after 
recalcification with CaCl2 to determine if there was a significant difference 






The results from the two groups were treated by Bland-Altman analysis. 
Apart from MCF values there was significant bias between all parameters 
measured in the two groups. The limits of agreement for all parameters 




We found that ROTEM EXTEM® results from EDTA samples were not 
comparable to or interchangeable with those from citrated samples. 
The difference in results is not due to differences in ionised calcium 
concentration levels in the samples post-recalcification as the ionised 
calcium concentrations in both groups post-recalcification were adequate 
for coagulation. 
EDTA samples did show superior consistency in all parameters and may 
be a suitable alternative for sample preservation for VET if reference 
















Rotational thromboelastometry (ROTEM®) is a whole blood coagulation 
test where clotting is activated by a biochemical agonist in a reproducible 
way. It is one of a few point-of-care devices used for viscoelastic testing. 
Specific reagents are available that standardize the in vitro coagulation 
process and also speed up the analysis, an advantage over conventional 
laboratory based coagulation screens. (Macey, Azam et al. 2002, Ganter 
and Hofer 2008) Viscoelastic tests (VET) assess the viscoelastic 
properties of blood samples under low shear conditions. It provides 
information about coagulation initiation, clot propagation kinetics, clot 
firmness, fibrin-platelet interaction and fibrinolysis.  
It plays an increasingly important role in the point-of-care management of 
bleeding patients in the acute perioperative period. (Ganter and Hofer 
2008, Bolliger, Seeberger et al. 2012, Espinosa and Seghatchian 2014, 
Karon 2014, Whiting and DiNardo 2014) 
 
In the ROTEM® EXTEM assay a 300µl whole blood sample is transferred 
to a plastic cup with a precision pipette. The cup is pre-warmed to 37⁰C 
and preloaded with tissue factor and calcium chloride. The reagent 
activates the tissue factor coagulation pathway and shortens the test 
duration. (Macey, Azam et al. 2002, Lang 2005, Ganter and Hofer 2008) 
This is similar to the prothrombin time (PT) test. The calcium chloride is 
necessary to replenish the ionized calcium in the sample that has been 
removed by the chelating agent. 
 
Conventionally, blood samples for laboratory coagulation testing such as 
prothrombin time and activated partial thromboplastin time (aPTT) and 
ROTEM® analysis are drawn into a Vacutainer® tube containing sodium 
citrate. (Horsti 2001, Macey, Azam et al. 2002) The sodium citrate inhibits 
clotting of the specimen via the action of the citrate ion to mildly chelate 
free ionized calcium, making ex vivo calcium unavailable to the 
coagulation system. (Whitten and Greilich 2000, James and Roche 2004, 
Lippi, Salvagno et al. 2010) 
 
Ethylenediamine tetraacetic acid (EDTA) is a polyprotic acid containing 
four carboxylic acid groups and two amine groups with lone pair electrons 
that strongly chelates calcium and several other metal ions in 1:1 metal 
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EDTA-complexes.  It is not routinely used for coagulation testing. (Horsti 
2000, Banfi, Salvagno et al. 2007, Lippi, Salvagno et al. 2010)  
 
Although there is literature that shows that conventional laboratory 
coagulation testing can be done on EDTA-treated blood samples (Horsti 
2001), citrate remains the anticoagulant of choice as the results obtained 
are more consistent.(Lippi, Salvagno et al. 2010)  
 
In our institution we have stock issues from time to time and availability of 
citrated Vacutainer® tubes have been problematic. A universal sample 
would solve this problem as well as reduce the volume of blood collected 
from patients and reduce the number of venepunctures performed. 
 
No literature is available to ascertain if ROTEM® EXTEM (Rotational 
thromboelastography; TEM International, Munich, Germany) analysis 
results on EDTA-treated whole blood samples is compatible with those 
obtained from citrated samples. The aim of this study is to establish this 
and also to evaluate the ionized calcium levels in EDTA and citrate 
samples when recalcified as per ROTEM® protocol.  A study by Horsti et 
al found that total calcium levels in sample reagent mixtures for 
prothrombin testing are very similar after recalcification, resulting in 
comparable PT/INR results on EDTA and citrate-treated treated samples 
(with a correction factor).(Horsti 2000, Horsti 2001) A study published by 
James et al in 2004 showed that the minimum ionised calcium 
concentration  for initiation of  coagulation in vitro is 0.33 mmol/L and that 
in samples with Ca2+ levels above 0.56 mmol/L  clotting was normal in 
almost all whole blood samples. (James and Roche 2004) Both EDTA and 
citrate chelate calcium albeit with different affinities. This should not matter 
if samples are flooded with calcium prior to coagulation testing as is the 
norm with thromboelastography. 
 
If there is a significant difference in the ionized calcium levels after 
recalcification as per ROTEM® protocol, this might be the key factor in 
any differences in clotting parameters obtained 
 
Our hypothesis was that ROTEM® EXTEM parameters obtained from 
EDTA treated whole blood samples should be comparable to those 





Structured Literature review 
 
 
Objectives of the literature review: 
The main objective of this literature review was to evaluate the current 
published literature on the listed topics/points.  There is no published data 
on the use of EDTA (Ethylenediamine tetraacetic acid) treated blood 
samples in Rotational Thromboelastometry (ROTEM®) specifically, so a 
comprehensive review was made of the methodology of 
thromboelastogaphy and rotational thromboelastometry as well as factors 
that may influence results obtained. The two in vitro anticoagulants 
compared in my study were reviewed and specifically their influences on 
ionised calcium levels in the samples as this was believed to be the key 
factor in any potential differences in results. 
 
 
Method of literature review 
 
A PubMed literature search was performed using the free text and 
MeSH thesaurus terms listed below in different combinations. 
 
 ‘Anticoagulant’ 
 ‘Edetic acid’ 
 ‘EDTA’ 
 ‘Ethylenediaminetetraacetic acid’  
 ‘Pharmacology’   
 ‘Pre-analytical factors’  
 ‘Rotational thromboelastometry’  
 ‘ROTEM’ 
 ‘Sample’ 
 ‘Sodium citrate’  




 ‘Thromboelastography’  
 ‘Thromboelastometry’ 
 ‘Vacutainer’  
 ‘Viscoelastic test’ 
 ‘Viscoelastic’  
 
A Google Scholar search was performed using the same terminology. 
Relevant research papers were identified by their abstracts.  An author-
date referencing method was used. 
Further appropriate papers were identified by searching reference lists of 
relevant published papers.  
Device manuals and manufacturer’s guidelines were obtained via Google 
search. 
 
Blood sample preservation for laboratory testing 
 
An anticoagulant is often added to a blood sample or specimen to 
maintain blood in a fluid state for diagnostic laboratory testing.  There are 
a number available commercially and suited for different types of 
laboratory analysis. 
 
Properties of the ideal anticoagulant:  
Enable laboratory to obtain suitable plasma from the sample for clinical 
chemistry analyses and coagulation studies 
Not expensive 
A universal coagulant will optimise laboratory workflow, sample volume 
and turnaround time. (Banfi, Salvagno et al. 2007) 
Preserve activation status of platelets until samples are analysed (Macey, 
Azam et al. 2002) 
Does not affect staining properties. 
Halt enzyme processes completely until reactivation by another reagent. 
10 
 
As EDTA and Sodium Citrate are the main anticoagulants in use for in 
vitro testing and the anticoagulants compared in this study, a 
comprehensive review was done on their indications, methods of action 
and limitations. 
 
Sodium Citrate as in vitro anticoagulant  
Sodium citrate is primarily used as an anticoagulant for coagulation 
studies. It has been used for over a century in coagulation testing.  In fact 
many studies showed that samples other than citrated plasma are 
unsuitable for coagulation testing as the results were unreliable and 
misleading.(Lippi, Salvagno et al. 2010) 
Commercially there are two solutions of sodium citrated evacuated tubes 
available namely 3.2% and 3.8%.  There is contradicting evidence as to 
what degree the solution used influences results. 
Sodium citrate causes less spontaneous activation of platelets in vitro 
than EDTA. Citrate causes no initial change in volume or shape of 
platelets when blood is collected, but it causes platelets to become 
spherical and increase in size over time.(Macey, Azam et al. 2002) 
Citrate binds calcium more avidly than magnesium and this may result in 
a relative increase in magnesium concentration in the citrated blood 
sample.(James and Roche 2004) 
A previous study by James et al showed that ionised magnesium had a 
negligible effect on clotting as measured by thromboelastography.(James 
and Roche 2004) 
Citrated plasma contains significantly reduced levels of potassium, 
chloride, calcium and magnesium, but sodium is markedly increased 
compared with native plasma.(Lippi, Salvagno et al. 2010) 
Lippi et al found that the mean total calcium level in citrated blood samples 
was 1.98 ± 0.02 mmol/l compared to our data where the ionised calcium 
level was undetectable prior to recalcification. The mean total calcium 
level in untreated serum in their study was 2.37 ± 0.003 mmol/l. The 
reason for this is that only ionised calcium is chelated by citrate. The free 
ionised calcium is also only mildly chelated by citrate according to this 
author. (Lippi, Salvagno et al. 2010) However it is only the ionised fraction 
that is relevant to coagulation. 
The difference between this study by Lippi and the one we are currently 
conducting is that the electrolytes were tested on the plasma component 
of blood only. Total calcium was evaluated as opposed to ionised calcium 
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and was assayed using a Roche/Hitachi Modular System P as opposed 
to a blood gas analyser as in our study.(Lippi, Salvagno et al. 2010) 
EDTA as in vitro anticoagulant. 
EDTA is the anticoagulant recommended for full blood counts and white 
blood cell differential analysis by the National Committee for Clinical 
Laboratory Standards. It has excellent cell preservation 
properties.(Macey, Azam et al. 2002, Stokol and Erb 2007) 
EDTA is a polyprotic acid that contains 4 carboxylic acid groups and two 
amine groups with lone pair electrons that bind to and chelate calcium and 
other metal ions in a 1:1metal –EDTA complex. It results in a strong bond 
with these metal ions like calcium that are cofactors for enzymatic 
processes and thus prevents some enzyme reactions. As calcium is an 
important cofactor for clotting enzymatic reactions (see discussion on 
calcium’s role in coagulation) it prevents the clotting of blood in the 
specimen tube which then remains in fluid state suitable for laboratory 
testing. EDTA results in the optimal extended stability of cells and particles 
in blood.(Banfi, Salvagno et al. 2007)   
Three different formulations of EDTA are available. In Europe and Japan 
 the dipotassium salt of EDTA (K2EDTA) is mostly used for cytometry as 
recommended by the International Council for Standardization in 
Haematology. In the United States and the United Kingdom the 
tripotassium salt (K3EDTA) is mainly used. (Macey, Azam et al. 2002, 
Banfi, Salvagno et al. 2007) 
K2EDTA does not result in dilution of blood samples as it is spray dried on 
the sides of the tube. This is important especially with small sample 
volumes.   
EDTA salts are hyperosmolar and can lead to a small degree of shrinkage 
of cells. K2EDTA has a smaller osmotic effect on cells than K3EDTA. This 
effect is not clinically important. 
Blood samples are stable in EDTA for up to 24 hrs and longer if stored at 
4⁰ Celsius. (Banfi, Salvagno et al. 2007) 
EDTA does not affect staining of smears with stains such as May- 
Grunwald Giemsa. (Banfi, Salvagno et al. 2007) 
It is used for the measurement of cytokines, protein and peptide and 
cardiac markers. (Banfi, Salvagno et al. 2007) 
The cytokine levels measured in plasma might be altered by EDTA if the 
stored sample is kept too long before separating the plasma. (Banfi, 
Salvagno et al. 2007) 
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EDTA plasma is one of the better agents for proteomics studies. It has a 
strong stabilising effect on several labile molecules and cause no plasma 
dilution that may influence the protein profile. (Banfi, Salvagno et al. 2007) 
EDTA is also used for measurements of certain drugs, cardiac markers, 
molecular biology, virology and infectious diseases. (Banfi, Salvagno et 
al. 2007) 
A limitation of EDTA is that it does not completely stabilise platelets. It 
may lead to changes in measured platelet count, mean platelet volume, 
mean platelet component, platelet activation and platelet aggregation. 
Platelets quickly becomes spherical when EDTA is added to a blood 
specimen. Initially they remain the same volume and then increase in size 
before decreasing again.(Macey, Azam et al. 2002)  
EDTA, especially K2EDTA is not recommended for tests of platelet 
adhesion as it may result in platelet activation immediately after blood 
drawing. This is more prevalent with K2EDTA and heparin than with 
citrate. (Banfi, Salvagno et al. 2007) 
EDTA may cause an increase in CD62P expression of the platelet and 
this combined with a decrease in MPC (mean platelet component) is an 
indicator of platelet activation. These changes are temperature 
dependant.(Macey, Azam et al. 2002) 
EDTA can cause in vitro platelet aggregation (clumping) and a 
pseudothrombocytopaenia.(Stokol and Erb 2007) The prevalence of this 
phenomenon is around 0.1% and more prevalent in samples from 
thrombocytopenic patients. This might influence platelet count in 
laboratory testing but does not usually signify platelet dysfunction or 
abnormalities. EDTA may cause structural changes in platelets that leads 
to the expression of GPIIb/IIIa on the cell surface. This complex exposed 
on the cell surface may trigger a reaction with IgM autoantibodies. This 
reaction is not induced or mediated by the calcium chelation effect of 
EDTA, but by other mechanisms. (Macey, Azam et al. 2002, Banfi, 
Salvagno et al. 2007, Stokol and Erb 2007) 
No anticoagulant currently in clinical use can prevent platelet activation 
but the degree depends on anticoagulant used. (Macey, Azam et al. 2002) 
EDTA has been used in studies to evaluate platelet status and function 
and if the effects of EDTA are taken in consideration the data could still 
be clinically useful, but its use in measuring platelet activation remains 
questionable (Macey, Azam et al. 2002) 
Calcium, iron and magnesium levels cannot be measured in EDTA 
samples due to chelation of these metal ions. K3EDTA contains markedly 
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increased potassium levels. Na2EDTA contains markedly elevated levels 
of sodium. Chloride levels are decreased in EDTA plasma. (Lippi, 
Salvagno et al. 2010) 
Thus, sodium and potassium levels cannot be measured correctly in a 
sample when they are used as a salt in the formulation. 
With newer automated and innovative tests the role of EDTA may need to 
be reviewed in haematology as EDTA may have influences on these tests 
that are unknown.  
 
The use of EDTA in coagulation testing 
A literature review was done to establish prior use of EDTA in coagulation 
tests. 
Prothrombin time (PT) is widely used to measure the effect of oral 
anticoagulant therapy.  PT is usually measured on blood collected into a 
collection tube and diluted or mixed with different preparations of sodium 
citrate. (Horsti 2001). The International Normalized Ratio (INR) was 
established to eliminate dependence on sensitivity of different reagents.   
Horsti et al tried to establish the similarity of INR and PT results in seconds 
between citrate and EDTA samples using the Owren method in patients 
on oral anticoagulation therapy. They used citrate based calibrators and 
a correlation equation to calculate INR and results in seconds for EDTA 
samples. They found a strong correlation between results obtained from 
the same patients, but a correlation equation needed to be used as the 
results differed numerically. (Horsti 2000, Horsti 2001) 
They found that the difference in results depended mainly on sample 
dilution by citrate solution and when the PT test was calibrated with normal 
EDTA plasma the differences disappeared.  There were no publications 
found on VET done on EDTA samples on humans. 
Crist et al also evaluated the use of EDTA in standard plasma coagulation 
testing and found the biggest differences between EDTA and citrate 
treated plasma was for prothrombin time, partial thromboplastin time as 
well as in functional assays for factors V, VIII, protein C and protein 
S.(Crist, Gibbs et al. 2009) They advise against the use of EDTA for 






Role of Ionised calcium in blood coagulation 
Calcium plays a vital role in in vivo coagulation. It is a co-factor for clotting 
factors V, VII, VIII, IX, X and XIII. It is also necessary for pro-thrombin to 
thrombin conversion and the formation of fibrin from fibrinogen.(James 
and Roche 2004) 
The physiological ionised calcium concentration in blood is 1.1-1.4 
mmol/L, which is well above the minimum levels of ionised calcium 
necessary for reactions in the coagulation cascade. 
Variation of ionised calcium concentrations should not have any 
significance on specific coagulation factor activation as long as it is above 
a certain threshold value. The aim of a study done by James et al in 2004 
was to obtain this threshold value by using VET on whole blood samples.  
The samples were citrated and then recalcified with varying amounts of 
10% calcium chloride. After recalcification the ionised calcium 
concentration in each sample was measured with a blood gas analyser 
and TEG® analysis was performed on the samples simultaneously. 
(James and Roche 2004) 
They found the threshold value for initiation of clotting was between 0.33 
and 0.39 mmol/L.  An ionised calcium concentration of 0.56 mmol/L was 
necessary for a normal r-, k-time and α –angles as per manufacturer’s 
normal values. An ionised calcium concentration of greater than 0.41 
mmol/L was adequate for normal maximal amplitude levels. They found 
no correlation between ionised calcium concentration and clot lysis in this 
study. They also found no correlation between increasing ionised calcium 
concentrations within the clinical range and any TEG® parameters 
obtained. (James and Roche 2004) 
Ataulluakhanov et al defined a lower limit of 0.25 mmol/L Ca 2+ for 
thrombin generation and an upper limit of 0.5 mmol/L Ca 2+ above which 
thrombin generation was not further enhanced. This study only looked at 
thrombin generation and not at other parameters of 
coagulation.(Ataullakhanov, Pohilko et al. 1994) 
The threshold of ionised calcium concentration necessary for platelet 
aggregation is 2 x 10-4 mmol/L which is much less than that required for 
fibrin formation. (James and Roche 2004) 
Calcium chelation does not inhibit contact activation in the specimen tube.  
This could explain why an accelerated trace is seen in stored citrated 
samples as the contact activation pathway up to the activation of factor IX 
continues in the presence of a calcium chelator and the activated 
precursors are “ready” when the sample is recalcified. (Roche and James 
2003) Overall, the literature suggests that VET results from citrated blood 
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Ionised calcium levels in blood samples for coagulation testing 
There is a paucity in the literature regarding ionised calcium 
concentrations in samples and the effect it has on coagulation results.   
Apart from the study by James already discussed, Horsti et al also found 
that in PT/INR testing using the Owren method the coagulation reagent 
contained sufficient ionized calcium to allow coagulation with either 
sample type (EDTA or Citrate). Ca2+ in their reaction mixtures after 
recalcification was 1.525 mmol/L for citrate and 1.708 mmol/L for EDTA. 
These measurements was done on the plasma component of blood 
only.(Horsti 2000) 
Lippi et al evaluated total calcium concentrations in native, citrated and 
EDTA plasma and found the values to be 2.37 mmol/L, 1.98 mmol/L and 
0.00 mmol/L respectively. The authors concluded that the total calcium 
concentration remained high in the citrated plasma due to the fact that 
citrate only binds ionised calcium.  
 
Principles of viscoelastic testing (VET) 
 
VET has become a popular monitoring mode for haemostasis and 
transfusion management in trauma, major surgery and haemophilic 
patients.  
It can be used as a point-of-care coagulation device in the operating 
theatre and emergency room reducing the time to obtain information 
regarding haemostasis to few minutes.(Bolliger, Seeberger et al. 2012) 
VET assesses clot formation, platelet function, fibrinogen levels, thrombin 
generation and clot breakdown in real time.  It is thus used to assess 
hyper- and hypo-coagulable states and to guide therapeutic interventions 
such as transfusion of platelets, fresh frozen plasma and coagulation 
factor concentrates.(Lang 2005, Bolliger, Seeberger et al. 2012, Whiting 
and DiNardo 2014) 
VET assesses the viscoelastic properties of clot formation under low 
shear conditions in whole blood. This is done after adding a specific 
coagulation activator such as tissue factor extracted from rabbit brain in 
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the case of the ROTEM EXTEM® assay. The interaction between 
activated platelet glycoprotein IIb/IIIa receptors and polymerising fibrin 
during thrombin generation results in a tensile or viscoelastic force 
between the cup of the device and an immersed pin. The tensile force is 
reduced by fibrin degradation by fibrinolysis. (Bolliger, Seeberger et al. 
2012, Whiting and DiNardo 2014) 
Two devices are commercially available namely TEG® 
(Thromboelastograph – Haemoscope/Haemonetics, Niles,Ill) and 
ROTEM® (Rotational thromboelastography; TEM International, Munich, 
Germany).(Ganter and Hofer 2008, Bolliger, Seeberger et al. 2012) They 
provide essentially the same information, but because of differences in 
operating characteristics the results are not interchangeable. They use 
different nomenclature to describe the same parameters.(Whiting and 
DiNardo 2014) 
A variety of activators and inhibitors are available to accelerate the test 
times on these devices and to obtain differential diagnostic information 
regarding a patient’s haemostatic status.(Lang 2005) Different activators 
and inhibitors isolate parts of the coagulation cascade that are then better 
evaluated. 
In the TEG® apparatus a metal pin that is suspended by a torsion wire is 
immersed in a metal or plastic cup containing whole blood. The disposable 
cup oscillates through a 4.75º angle around the fixed immersed pin.  The 
torque generated between the pin and cup by clotting of the blood is 
detected and transmitted electronically to a computer processing unit.  As 
the clot later dissolves the torque is diminished. It is then presented as a 
tracing of clot formation and dissolution over time. (Bolliger, Seeberger et 
al. 2012, Whiting and DiNardo 2014)  Clot formation is initiated by 
recalcification and (usually) stimulation of Factor XII by kaolin or celite.  As 
a result, since activation of FXII is not inhibited by chelation of calcium, 
citrated samples may show variable rates of activation unless stabilised 
for 30 minutes prior to testing (see below). 
The ROTEM® apparatus differs in that it consists of a plastic pin that 
rotates in a fixed cup made from polymethylmethacrylate through an angle 
of 4.75⁰. The torque generated is transmitted optically and not 
electronically.(Ganter and Hofer 2008) 
The ROTEM® instrument has four measurement channels that can be 
simultaneously and independently used compared with the TEG® 
system’s two channels.(Lang 2005, Bolliger, Seeberger et al. 2012) 
The ROTEM® system contains an automated pipetting system that allows 
mixing to be performed in a standardized way.(Lang 2005) 
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It is less sensitive to vibration than the TEG® apparatus.(Whiting and 
DiNardo 2014) 
The whole blood sample required for ROTEM® analysis is usually 
collected in a Vacutainer® tube containing sodium citrate. The sample is 
then recalcified when the blood sample is pipetted into the sample cup. 
Assays available on ROTEM®: 
EXTEM: Contains tissue factor as activator of the extrinsic pathway. 
INTEM: Ellagic acid and phospholipids. Evaluation of intrinsic pathway. 
HEPTEM: INTEM plus heparin inhibitor. Compared to INTEM analysis to 
evaluate heparin effect. 
FIBTEM: Cytochalasin D inhibits platelet function after tissue factor (TF) 
activation. When compared to EXTEM analysis allows qualitative analysis 
of fibrinogen contribution to clot strength. 
APTEM: Aprotinin to inhibit plasmin and fibrinolysis and EXTEM reagent. 
Compared with EXTEM analysis to evaluate fibrinolysis. (Lang 2005, 
Bolliger, Seeberger et al. 2012, Whiting and DiNardo 2014) 
Results obtained from native bloods samples cannot be directly compared 
to those from citrated samples that has been recalcified.  
Compared with the TEG® device intra- and inter- individual operator 
variability was superior with ROTEM®.(T.Haas 2014) 
ROTEM® Parameters: 
As our study was done using the ROTEM® device an overview of 
ROTEM® parameters are included. 
 
CT: Clotting time (equivalent to TEG® R–time) 
CFT: Clot formation time (equivalent to TEG® K-time) 
α- angle: Alpha angle (equivalent to TEG®) 
MCF: Maximal clot firmness (equivalent to TEG® MA) 
A5 –A30: Amplitude at 5-30 minutes 
CLI30-CLI60: Clot Lysis Index 
(Whiting and DiNardo 2014) 
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The most important parameters obtained from ROTEM® are the 
amplitude or clot firmness which represent the viscoelasticity of the 
sample (MCF). 
Additional parameters are obtained from the time course of viscoelastic 
changes. It depicts the rate and stability of clot formation e.g. CT, CFT, α 
(angle at 2 mm amplitude) and Lysis times. (Bolliger, Seeberger et al. 
2012)  
The clotting time (CT) reflects initial fibrin formation after thrombin 
generation. It is defined by the computerised trace reaching an amplitude 
of 2 mm.(Lang 2005, Ganter and Hofer 2008, T.Haas 2014) 
Clot formation time (CFT) is the time is takes for amplitude to increase 
from 2 to 20 mm and alpha angle (α) is the tangent of the slope during this 
period. (Lang 2005, T.Haas 2014) 
Maximum clot firmness (MCF) is the maximal amplitude of the curve and 
can be reliably predicted from A5 and A10 values. It signifies the 
maximum firmness the clot achieves. Platelet activation and aggregation, 
fibrin polymerisation and cross-linking by factor XIII all play a role in MCF. 
(T.Haas 2014) 
A5 – A30 values signify the clot strength after the respective time intervals. 
(Lang 2005, T.Haas 2014) 
The clot lysis index describes degree of fibrinolysis at the specific time. 
Reference ranges for ROTEM EXTEM® assay: 
CT: 42-77 seconds 
CFT: 46 – 148 seconds 
α - angle: 63 – 81 ⁰ 
A10: 43 -65 mm 
MCF: 49 – 71 mm 
These reference ranges were obtained from a multi-centre investigation 
on reference ranges for ROTEM® done by Lang et al in 2004. The 
ROTEM® user manual refers to this study by Lang for reference 
ranges.(Lang 2005, Pentapharm 2007, Bolliger, Seeberger et al. 2012) 
TEG® parameters and reference ranges will not be discussed as 




Preanalytical factors playing a role in VET 
Reference ranges in VET depend to some degree on pre-analytical 
factors. Multiple studies have been done on both the TEG® an ROTEM® 
systems to evaluate the influence of these factors on reference ranges 
and reproducibility.  
Threshold values for haemostatic interventions or clinical outcomes 
should be locally evaluated for each system and available 
components/reagents used.(Bolliger, Seeberger et al. 2012) 
Method of sample acquisition 
Platelet activation and tissue factor contamination during venepuncture 
will affect VET results. It is important to minimize tissue trauma during 
venepuncture. In animal studies the R-time (TEG®) was shortened with 
poor venepuncture technique. The use of a discard tube (where first few 
millilitres of blood obtained are discarded) mitigates the effect of a 
traumatic venepuncture and is good practice.(Flatland, Koenigshof et al. 
2014) 
Any large vessel with free flowing blood can be used for sampling. 
The use of 21g or larger needles is recommended as well as the use of 
evacuated tubes for collection of blood. If blood is taken from a central line 
contamination with heparin should be considered. The method for 
collection and storage of blood in an institution should be standardised for 
clinical studies and to evaluate serial sampling in a patient in a clinical 
scenario to eliminate the contribution of preanalytical factors. Method 
specific reference ranges should be used if they are available (Flatland, 
Koenigshof et al. 2014) 
A recent review paper found no studies comparing results from arterial 
and venous blood.(Flatland, Koenigshof et al. 2014) 
The use of an anticoagulant 
There are quite a few studies on the effect of citrate and specifically the 
time the citrated sample were stored on results obtained in VET. 
James et al found that recalcified citrated samples has shortened R –and 
K- times and an enhanced α-angle when compared to native whole blood 
samples when evaluated with TEG®.  This was prevalent in samples 
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stored at room temperature as well as those that were refrigerated. The 
maximal amplitudes of the samples remained unaffected.  This result of 
relative hypercoagulability found in citrated samples were also obtained 
by Camenzind et al. (Camenzind, Bombeli et al. 2000, Roche and James 
2003) 
This was ascribed to the incomplete inhibition of the activation of the 
coagulation cascade in the sample while it was stored. (Zambruni, 
Thalheimer et al. 2004) 
The concentration of the anticoagulant will also play a role.  
Transport of sample 
There is some evidence that transport of the sample in a pneumatic tube 
system may alter results, but this is of no relevance to the present 
study.(Martin, Schuster et al. 2012, Espinosa and Seghatchian 2014, 
Flatland, Koenigshof et al. 2014) 
Sample storage time and temperature 
Animal studies showed that for tissue factor activated TEG®, samples that 
has been stored for a prolonged time appeared hypercoagulable when 
compared to samples stored for a shorter period. 
Strong coagulation activators might eliminate the effects of prolonged 
sample storage.(Flatland, Koenigshof et al. 2014) 
Camenzind et al showed stability in samples stored for up to 8 hours when 
a potent activator of coagulation (Celite) was used.(Camenzind, Bombeli 
et al. 2000, Zambruni, Thalheimer et al. 2004) 
Animal studies found that in refrigerated samples (4⁰C) CT, MCF was 
significantly higher and α-angle significantly lower when compared to 
room temperature samples. There does not appear to be any major 
difference in samples stored at room temperature and those kept at 37⁰C 
for up to 30 minute storage times.(Flatland, Koenigshof et al. 2014).  
Roche and James found a hypercoagulable trace in refrigerated samples 
as well that they ascribed to cold activation of factor VII and 
platelets.(Roche and James 2003) 
Martin et al found a prolonged ROTEM EXTEM® CT after 30 minutes of 
storage of citrated samples. (Martin, Schuster et al. 2012)] 
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Theusinger et al found no differences in EXTEM®, INTEM® and 
FIBTEM® assays over 2 hours of storage.(Martin, Schuster et al. 2012) 
Bohner and von Pape found that for ROTEM® analysis citrated samples 
could be stored for up to 4 hours without clinically significant changes in 
the results.(Bohner and von Pape 2003, Lang 2005) 
Repeated sampling 
There is a trend towards hypercoagulability when repeated sampling is 
done on the same specimen. Repeated sampling leads to reduced R- 
times, K-times as well as increased α- angle. The contact activated 
coagulation pathway is probably activated by repeated sampling. 
(Zambruni, Thalheimer et al. 2004) 
System and activators used   
The use of a potent activator significantly reduces changes observed 
during sample storage compared to non-activated tests.(Lang 2005, 
deLaforcade, Goggs et al. 2014) 
CT and CFT are strongly dependant on the type and concentration of 
activator.   
There is more variation in results with kaolin based tests such as TEG®. 
Variation is less with tissue factor activated tests such as EXTEM. 
Variation is least for MA/CFT, independent of reagent used.(Bolliger, 
Seeberger et al. 2012) 
Haematocrit of sample 
There are studies that show hypercoagulable TEG® tracings in samples 
that were haemodiluted to haematocrits of 10-30% (Bolliger, Seeberger et 
al. 2012) 
Haematocrit values below 25% results in an increased FIBTEM® MCF. 
This is due to an increased plasma fraction in the sample. The correlation 
between plasma fibrinogen levels and FIBTEM® MCF levels are 





Usefulness of VET in clinical settings 
 
The management of a bleeding patient is quite complex. Therapeutic 
interventions range from the transfusion of whole blood or allogeneic 
blood components to specific procoagulant drugs and purified clotting 
factors or a combination of the above.(T.Haas 2014) 
The therapeutic intervention may be empiric, based on standard plasma 
coagulation tests or from the results of point-of-care devices.(T.Haas 
2014, Whiting and DiNardo 2014) 
The goals of intervention are to stop bleeding, minimize risk of thrombotic 
events and to reduce the transfusion of allogenic blood products.(Whiting 
and DiNardo 2014)  
There is some evidence that VET-based algorithms reduce transfusion 
requirements and blood loss in massive trauma, cardiac surgery and liver 
transplantation.(Kang, Martin et al. 1985, Bolliger, Seeberger et al. 2012, 
Karon 2014, Whiting and DiNardo 2014) (Espinosa and Seghatchian 
2014) 
The liberal transfusion of blood products has been associated with 
complications such as increased mortality, transmitted infections and 
organ dysfunction.(Bolliger, Seeberger et al. 2012) 
Algorithms to guide transfusions based on VET have been implemented 
successfully. VET-based transfusion algorithms in paediatric cardiac 
surgery leads to reduced post-operative blood loss, reduced need for 
transfusion and a shorter intensive care unit stay. (Nakayama, Nakajima 
et al. 2014) 
It should be noted however, that the cut-off values for transfusion are not 
well validated at this time. Serial VET measurements are useful in guiding 
haemostatic interventions, but should be used in conjunction with other 
clinical and laboratory parameters. The patient’s body temperature, 
haematocrit and acid-base status should be taken in consideration. A 
normal VET may indicate that further surgical exploration is warranted in 
a bleeding patient.(Whitten and Greilich 2000, Bolliger, Seeberger et al. 
2012) 
It is important to understand the limitations and working principles of VET 
when interpreting results and using it to guide haemostasis therapy. Using 
it correctly may result in optimizing goal directed transfusion therapy and 
thus avoiding empirically administrating large volumes of multiple 
components and the related morbidity and mortality.(Bolliger, Seeberger 
et al. 2012, Whiting and DiNardo 2014) 
23 
 
Limitations of VET 
 
The global nonspecific nature of the VET measurements may be both its 
greatest weakness and strength. Although specific coagulation assays 
does not necessarily  correlate with blood loss, they do provide specific 
diagnoses that respond to specific treatments.(Whitten and Greilich 2000) 
TEG® and ROTEM® are both moderately complex devices to operate 
requiring trained personnel. They require frequent stringent quality control 
procedures.(Ganter and Hofer 2008, T.Haas 2014) 
If situated in a centralized laboratory it requires a rapid transport system 
as well as a computer and network for online display of results to reduce 
turnaround times.(Bolliger, Seeberger et al. 2012). The procedures for 
transport should be standardised otherwise it may influence 
reproducibility of results. 
Pin slippage or vibration of the testing platform may result in artefacts and 
aberrant results. (Karon 2014) 
A variety of other preanalytical factors may influence VET results. These 
factors were discussed previously. 
VET is performed under low shear stress / no flow conditions and in the 
absence of endothelial cells.(Ganter and Hofer 2008, Espinosa and 
Seghatchian 2014, T.Haas 2014) 
The positive predicted value of ROTEM® in elective surgery to predict 
bleeding is limited. As with standard plasma coagulation tests the patient’s 
clinical condition and evidence of active bleeding should be considered 
before any therapeutic intervention. 
The negative predictive value of ROTEM® is high, thus ongoing bleeding 
with a normal ROTEM® result is indicative of surgical bleeding.(Haas, 
Fries et al. 2014) 
ROTEM® is not very sensitive in detecting platelet function disorders or 
the effect of anti-platelet drugs.(T.Haas 2014). It is not possible to 
distinguish bleeding as a result from thrombocytopaenia and dilutional 
coagulopathy when using a single ROTEM® assay activated with kaolin.  
Parallel EXTEM® and FIBTEM® analysis is necessary to distinguish 
hypofibrinogaemia from thrombocytopaenia. The Claus determination of 
fibrinogen levels remain a superior functional fibrinogen 
assessment.(Whiting and DiNardo 2014)  
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There is still limited conclusive evidence and a lack of adequately powered 
outcome studies on the success of VET in predicting bleeding and 
changing perioperative clinical outcomes.  
This together with a lack of the quality-assurance methodologies required 
by regulatory agencies such as the Food and Drug Administration (FDA), 
limits the acceptance of point-of-care viscoelastic tests.(Whitten and 







Ethical approval was obtained from University of Cape Town Human 
Research Ethics Committee. 
This was a volunteer study with blood samples taken from individuals 
giving written informed consent for the procedure. Eligible volunteers 
included adults between the ages of 18-65 years of age without detectable 
intercurrent disease. Excluded was any individual currently treated with 
any potentially coagulation-altering agent or with an intrinsic coagulation 
abnormality. Pregnant individuals were also excluded. 
Ten ml of venous whole blood was obtained from twenty healthy 
volunteers by venipuncture from an antecubital vein. A tourniquet was 
lightly applied to the upper arm. An 18G butterfly needle was used and 
the blood collected with the Vacutainer® system and sampling tubes.  The 
first Vacutainer® tube containing 3ml of blood drawn was discarded. 
Four ml of obtained blood was drawn into a Vacutainer® tube containing 
7.2 mg freeze – dried K3EDTA. The tube was inverted 3-4 times to ensure 
adequate mixing of the specimen.  A further 2.7 ml of obtained blood was 
immediately transferred into a silicon- coated glass Vacutainer® tube 
containing 0.5 ml of buffered sodium citrate. This results in a 0.109 M 
(3.2%) solution containing 1 part citrate to 9 parts blood. The tube was 
inverted 3-4 times to ensure adequate mixing of the specimen. 
In a previous study by Bohner et al. it was shown that the citrated samples 
used for ROTEM® can be stored up to 4 hours at room temperature 
without any clinically significant changes to the results obtained. (Bohner 
and von Pape 2003) 
 
All samples were stored for 15 minutes and warmed to 37 degrees Celsius 
prior to testing. Although waiting 30 minutes may have resulted in more 
comparable results between the two types of anti-coagulant, such a delay 
would obviate one of the main advantages of a point-of-care test, namely 
fast availability of results  
The samples were processed as per ROTEM®-EXTEM protocol: 20 μl of 
the EXTEM reagent (recombinant tissue factor and phospholipids, 
heparin inhibitor, preservatives and buffer) and 20μl of the recalcification 
agent (0.2 mol/l CaCl₂ in HEPEs buffer pH 7.4 and 0.1% sodium acide) 
were added into the pre-warmed cup of the ROTEM® analyzer. Then 300 
μl of blood was pipetted from the sample obtained using the provided 
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electronic ROTEM® precision pipette. Rotation thromboelastometry by 
ROTEM®-EXTEM system was performed simultaneously on the 2 
different samples from the same participant. The tests were performed on 
all samples by the same trained technologist.  
The test ran until conclusion and the following parameters were obtained:  
Clotting time (CT) – period to 2 mm amplitude 
Clot formation time (CFT) – period from 2 to 20 mm amplitude 
α-angle (α) – clot strengthening - slope of tangent at 2 mm amplitude 
Maximum clot firmness (MCF) - maximum amplitude 
 
One ml of the remaining blood in each specimen tube was drawn into a 
heparin-coated syringe and the Ca2+ concentration measured by the 
calcium electrode of an ADL 800 BASIC blood gas analyzer. 
Another ml of the remaining blood in each specimen tube was recalcified 
to the same concentration as that of the sample processed by ROTEM® 
in a clean, non-coated polypropylene/plastic tube. Please see addendum 
A for the calculation. This recalcified sample was drawn immediately into 
a heparin-coated syringe and the Ca2+ measured by the calcium electrode 
of an ADL 800 BASIC Blood gas analyzer. The analyzer was calibrated 
against standardized calcium solutions daily.  
 
The data obtained was exported and tabulated using Microsoft Excel 
software. 
 
The two groups of ROTEM® results from each type of sample were 
treated by Altman and Bland analysis to establish bias and to examine the 
limits of agreement and to determine whether or not these are in an 
acceptable range.(Martin Bland and Altman 1986)  The median values, 
standard error and 95% CI were obtained using the statistical program 
Statistica Version 12 and were compared to the respective reference 
ranges provided by the manufacturer.(Lang 2005) 
There are no studies on coagulation differences between citrated and 
EDTA-treated samples to allow for a meaningful power calculation.   
 
However, Crist et al compared citrate and EDTA- treated samples 
across a variety of coagulation measures (including PT and PTT, but not 
ROTEM) and found significant differences between them in 10 healthy 
volunteers.(Crist, Gibbs et al. 2009)  Thus, for the primary outcome 
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variable, coagulation, a minimum of 10 samples ought to suffice for a 
meaningful comparison. 
 
For the ionized calcium measurements, the Ca2⁺ concentration prior to 
and after recalcification were compared between the two groups using 
paired t-tests. From the work of Lippi et al, it is likely that the calcium 
concentration in the citrated samples would be at least 10 times that in 
the EDTA treated samples with a SD of 0.1 mmol/L. (Lippi, Salvagno et 
al. 2010) On this basis, only 6 samples would be required for a 90% 
power at an alpha value of 0.05.  Similarly, a power calculation based on 
the work of Horsti et al suggests that, after recalcification, the difference 
in calcium concentration between EDTA- treated and citrate-treated 
samples was 1.52 versus 1.71 mmol/L with a SD of 0.07.(Horsti 2000) 
Based on these numbers, even allowing for an increased variability and 
a SD of 0.1, 6 samples would be sufficient to establish differences in 
calcium concentrations at an alpha level of 0.05 and a power of 90%.  
 
Thus, 20 samples in each treatment group (obtained by splitting the 
10ml blood samples taken from 20 participants) were considered to 
provide sufficient information for a meaningful Altman and Bland 
analysis and would provide more than enough statistical power to 
explore differences in coagulation measures and ionized calcium 







There were substantial differences between the results obtained from the 
citrated and EDTA samples. 
In the Altman and Bland analysis of CT, there was a considerable bias of 
20.5 seconds, with the EDTA samples showing a significantly longer CT.  
The limits of agreement (3.82 to -44.7 sec) were also unacceptably wide.  
The mean values for CT were significantly different (see table 1).  The 
Altman and Bland analysis together with the box and whisker plots of 
these results are shown in figures 1(a) and 1(b). 
CFT also showed a substantial bias between the samples, but for this 
measure, the EDTA samples showed a faster clot formation time.  The 
limits of agreement were also wide, demonstrating that the two sample 
types are not interchangeable.  There was a statistically significant 
difference in CFT between the two groups.  These results are summarised 
in figures 2(a) and 2(b) and in table 1. 
The α-angle showed minimal bias between the samples and acceptable 
limits of agreement.  Although these results were statistically significantly 
different, there was no clinically important difference between them.  
However, the α-angle was larger for the EDTA sample group. These 
results are summarised in figures 3(a) and 3(b) and in table 1. 
MCF was similar between the groups with no statistically significant 
differences.  The Bland and Altman plot showed minimal bias and 
acceptable limits of agreement, indicating that the final clot strength in the 
two sample groups was interchangeable. These results are summarised 
in figures 4(a) and 4(b) and in table 1. 
The ionised calcium (Ca2+) concentrations showed substantial differences 
between the two groups that was highly significant (Table 1). 
We did not compare Lysis parameters as previous work indicated that 










Figure 1a and b.  Box and whisker plot of CT results for each specimen 



























Figure 2a and b.  Box and whisker plot of CT results for each specimen 






























Figure 3a and b.  Box and whisker plot of CT results for each specimen 






























Figure 4a and b.  Box and whisker plot of CT results for each specimen 


























Measure Group Mean Range 95%% CI SD p Ref 
CT (sec) Citrate 57.6 29-93 52.0-63.3 11.91 <0.0001 42-77 
EDTA 78.1 62-96 74.1-82.2 8.7 
CFT (sec) Citrate 86.7 48-124 77.3-96.2 20.1 <0.001 46-148 
EDTA 66.7 45-97 60.0-73.5 14.3 
α-angle (°) Citrate 72.8 65-81 70.1-74.7 4.0 0.001 63-81 
EDTA 76.6 71-81 75.3-77.9 2.8 
MCF (mm) Citrate 65.5 56-75 63.0-68.0 5.3 0.1 49-71 
EDTA 68.2 60-77 65.9-70.5 4.8 
Ca2+ 
(mmol/L) 
Citrate 3.8 3.2-4.2 3.6-3.9 0.3 <0.0001  
EDTA 7.6 6.1-8.6 7.3-8.0 0.7 
 
Table 1. EXTEM and calcium results of the two groups.  Ca2+ - ionised 






























As expected, ionised calcium levels were undetectable in all samples prior 
to recalcification in our study.  The mean Ca2+ concentrations in both the 
EDTA and citrated groups post-recalcification were well above the 
minimal value for coagulation as established by James et al in 2004. The 
mean value in the EDTA group was 7.62 mmol/L and 3.77 mmol/L in the 
citrate group. 
 
It is interesting that the mean ionised calcium is much higher in the EDTA 
treated group than in the citrated group. Previous studies alluded to the 
fact that EDTA binds calcium irreversibly and to a higher degree than does 
citrate and that is the reason for EDTA not being a suitable anticoagulant 
for in vitro coagulation testing. (Lippi, Salvagno et al. 2010). Our results 
do not reflect this enhanced calcium binding with EDTA and the reasons 
for this are not clear. Lippi et al evaluated total calcium concentrations in 
native, citrated and EDTA plasma and found the values to be 2.37 mmol/L, 
1.98 mmol/L and 0.00 mmol/L respectively. The fact that the total calcium 
concentration remained high in their citrated plasma could be due to the 
fact that citrate only binds ionised calcium and they measured total plasma 
calcium. 
 
It seems that recalcifying of the ROTEM® samples leads to supra- 
physiological levels of ionised calcium in both groups. There is no positive 
correlation between Ca2+ concentration and coagulation as measured by 
the TEG® system once a threshold of 0.56 mmol/L is reached. James et 
al found  that there is no inhibition of clotting as a result of hypercalcaemia, 
apart from a weak negative correlation between MA and ionised calcium 
concentrations, but the Ca2+ concentrations we obtained in this study are 
well above the levels they investigated.(James and Roche 2004) 
 
As discussed in the literature review, VET results from citrated samples 
are influenced by the duration of sample storage. It is possible that citrate 
takes longer to completely chelate calcium and that this results in a 
shortened CT compared to EDTA. As our samples were only stored for 
15 minutes before VET was performed, there might have not been enough 
time for the citrate to completely chelate the calcium in the specimen 
tubes. (Martin, Schuster et al. 2012). Although ionised calcium 
concentrations were zero in all samples in both groups prior to 
recalcification, the ionised calcium concentrations were not measured 
immediately after the ROTEM analyses were performed.  
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Although waiting 30 minutes may have resulted in more comparable 
results between the two types of anti-coagulant, such a delay would 
obviate one of the main advantages of a point-of-care test, namely fast 
availability of results. 
It would be interesting to evaluate the effect that the time of storage has 
on EDTA preserved samples. If EDTA binds ionised calcium faster than 
citrate, more consistent results over different storage times might be 
obtained. 
Mann et al suggested the collection of blood into citrate results in 
alterations that are not reversible by Ca2+ replacement. It seems that 
sodium citrate has an influence on the dynamics of thrombin generation 
after tissue factor activation that is independent of chelation.(Mann and 
Whelihan 2007) 
As the differences in clotting parameters are not fully explained by 
differences in ionised calcium concentrations between the two groups, 
there must be another unmeasured effect of the anticoagulant on the 
sample. 
We know that calcium chelation by citrate does not inhibit contact 
activation in the specimen tube.  This could explain why an accelerated 
trace is seen in stored citrated samples as the contact activation pathway 
up to the activation of factor IX continues in the presence of a calcium 
chelator and the activated precursors are “ready” when the sample is 
recalcified. (Roche and James 2003) It is unclear if EDTA inhibits contact 
activation to a higher degree than citrate.  
It has been shown that the electrolyte composition of samples after 
anticoagulation with citrate and EDTA differs vastly depending on the 
specific formulation used. This is why EDTA and citrate samples are not 
suitable for chemistry testing (Banfi, Salvagno et al. 2007, Lippi, Salvagno 
et al. 2010, Lima-Oliveira, Salvagno et al. 2014).  It is not known if the high 
potassium levels might play a role in the prolonged initiation of clotting as 
seen with the EDTA group.  
The parameters indicative of clot formation kinetics and maximal clot 
strength show that the EDTA samples appear hypercoagulable compared 
to the citrate group, despite the relatively delayed onset of initial clot 
formation. 
The slightly greater alpha angle in the EDTA-treated samples might reflect 
better preserved platelet function, but the similar CFT results argue 
against this. 
Although statistically different values were obtained for CT, CFT and α-
angle parameters for EDTA and citrated samples, the range, 95% CI and 
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standard deviation (SD) for EDTA for all these parameters were 
significantly smaller than those obtained with citrate (Table 1). 
These measures suggest that results from the EDTA samples are more 
consistent and show smaller variability (if not numerically similar) 
compared to those obtained from citrates samples. EDTA might be a good 
alternative if a reference range for EDTA samples can be established. The 









We found that ROTEM EXTEM® results obtained from EDTA samples 
were not comparable to or interchangeable with those from citrated 
samples. 
The difference in results is not due to differences in ionised calcium 
concentration levels in the samples post-recalcification, as the ionised 
calcium concentrations in both groups post-recalcification were adequate 
for coagulation. 
EDTA samples did show superior consistency in all parameters and may 
be a suitable alternative for sample preservation for VET if reference 
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The STARTEM® reagent supplied by the manufacturer of ROTEM® 
provides 0.2 mol/l or 0.2 mmol/ml CaCl2. 
For the ROTEM EXTEM® assay 20µl STARTEM® reagent and 20µl 
EXTEM® reagent are added to 300 µl of blood. A total sample volume of 
340µl is added to the cup of the device. 
20 µl of the 0.2 mmol/ml STARTEM® reagent contains 0.004 mmol CaCl2   
(0.02ml x 0.2 mmol/ml) 
The concentration of CaCl2 in the 340 µl recalcified ROTEM® sample is 
thus 0.01176471 mmol/ml  
(0.004 mmol x 1𝑚𝑙
0.34𝑚𝑙
= 0.01176471 mmol/ml) 
This is the concentration of CaCl2 we aimed to obtain in our blood samples 
for ionized calcium testing after recalcification so that it is the same as that 
of the ROTEM® samples prior to testing. 
A total sample volume of greater than 1.5 ml is required for the ADL 800 
BASIC Blood gas analyzer we used to measure ionized calcium 
concentration s in our samples. 
The CaCl2 concentration available at our institution is 6.8 mmol in 10 ml 
(0.68 mmol/ml) 
To get to a concentration of CaCl2 similar to that of the ROTEM samples 
after recalcification (0.01176471 mmol/ml) we added 26.427µl CaCl2  to 
1500µl of blood taken from each type of Vacutainer® tube providing a 
sample of 1526.427 µl in total which was then added to a Pico® 
heparinised blood gas analysis syringe. Electronic precision pipettes were 
used. 
To simplify the volumes for pipetting the calculation was made as follows: 
 0.01176471𝑚𝑚𝑜𝑙/𝑚𝑙
0.68𝑚𝑚𝑜𝑙/𝑚𝑙
 𝑥 1 𝑚𝑙  = 0.01176471𝑚𝑚𝑜𝑙/𝑚𝑙
0.68𝑚𝑚𝑜𝑙/𝑚𝑙
 𝑥 1000𝑢𝑙 = 17.30104 µl  
1000 µl sample - 17.30104 µl CaCl2 of 0.68 mmol/l CaCl2 = 982.69896 µl 
blood 
Thus 17.30104 µl CaCl2 added to 982.69 ml of blood will give us the 
desired concentration of 0.117 mmol/l CaCl2 in a total sample of 1ml 
40 
 
To calculate the volume CaCl2 needed to be added to 1.5ml of blood as 
we planned to do: 
17.301µl x 1500𝑢𝑙
982𝑢𝑙
 = 26.427 µl CaCl2  
Thus we had a sample of 1526.427 µl in total (1500 µl blood + 26.427 µl 
CaCl2) in the Pico® syringes after recalcification. 
To test our calculation: 
26.427 µl (0.026427 ml) x 0.68 mmol/ml = 0.01797036 mmol CaCl2 
0.01797036 mmol 
1.526 𝑚𝑙
 = 0.117 mmol/l which is the desired concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
